Status:
COMPLETED
Cabergoline in Nonfunctioning Pituitary Adenomas
Lead Sponsor:
University of Sao Paulo General Hospital
Conditions:
Pituitary Adenoma
Nonfunctioning Pituitary Adenoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Clinically nonfunctioning pituitary adenoma remains the only pituitary tumor subtype for which no effective medical therapy is available or recommended. We will evaluate the use of cabergoline in a cl...
Detailed Description
Nonfunctioning pituitary adenomas (NFPA) are common tumors of sellar region characterized by the absence of clinically hormonal pituitary secretion. These adenomas are typically not diagnosed until th...
Eligibility Criteria
Inclusion
- presence of pituitary tumor rest at 6 months after neurosurgery
- absence of previous hormonal pituitary hypersecretion
- absence of previous radiotherapy and/or radiosurgery
- Histopathological exam showing pituitary adenoma
Exclusion
- ACTH immunoexpression at histopathological exam
- presence of previous radiotherapy and/or radio surgery
- psychotic psychiatric disease
- moderate or severe alterations in cardiac valves
Key Trial Info
Start Date :
February 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2017
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT03271918
Start Date
February 1 2015
End Date
August 1 2017
Last Update
September 7 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Laboratorio de Investigacoes Medicas 25
São Paulo, São Paulo, Brazil, 01402003